PRINCETON, N.J., and PARIS, Feb. 10, 2010-Medical device pioneer Stentys announced today that results of its expanded ‘OPEN-I’ clinical study will be disclosed by Stefan Verheye, M.D., Ph.D., on Friday, Feb. 12, during the upcoming Joint Interventional Meeting (“JIM”) 2010 in Rome. Dr. Verheye will present for the first time an analysis of the OPEN-I study and its extension with DES-i.e., a pool of data comprising 60 Stentys patients (27 DES and 33 BMS) who were followed-up angiographically after six months.
The self-expanding and disconnecting features of Stentys stents, unrivaled in the industry, are designed to ensure optimal apposition to a vessel as well as provide access to secondary side-vessels.
About Stentys
Based in Princeton, N.J., and Paris, Stentys intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure. The Company announced in December 2009 that it has started enrolling patients in the randomized APPOSITION II clinical trial to compare the Stentys self-expanding stent against conventional stents in treating AMI patients, looking specifically at stent apposition and adaptation to vessel growth. Stentys was co-founded by Gonzague Issenmann and Jacques Séguin, M.D., Ph.D., founder of CoreValve, which was acquired last year by Medtronic for $700 million plus earn-outs.
